1. Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule
   Emiliano Calvo et al, 2004, Clinical Cancer Research CrossRef
2. Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
   George R. Simon et al, 2006, Clinical Cancer Research CrossRef
3. Phase I Clinical and Pharmacodynamic Evaluation of Oral CI-1033 in Patients with Refractory Cancer
   Ralph G. Zinner et al, 2007, Clinical Cancer Research CrossRef